Anna Berkenblit
Director/Board Member en SURROZEN, INC. .
Fortuna: 3 M $ al 31/01/2024
Cargos activos de Anna Berkenblit
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SURROZEN, INC. | Director/Board Member | 01/08/2018 | - |
| Independent Dir/Board Member | 01/08/2018 | - | |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 14/03/2019 | - |
Historial de carrera de Anna Berkenblit
Antiguos cargos conocidos de Anna Berkenblit.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 01/04/2015 | 31/08/2023 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01/01/2013 | 01/01/2015 |
| AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2011 | 01/01/2013 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2007 | 01/09/2011 |
Formación de Anna Berkenblit.
| Harvard University | Graduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 11 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Graduate Degree | 2 |
| Corporate Officer/Principal | 2 |
Sectorial
| Health Technology | 7 |
| Consumer Services | 4 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Anna Berkenblit
- Experiencia
